Total Payments
$3,548
2024 Payments
$750.62
Companies
30
Transactions
204
Medicare Patients
1,625
Medicare Billing
$292,283
Payment Breakdown by Category
Food & Beverage$3,541 (99.8%)
Education$6.80 (0.2%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $3,541 | 203 | 99.8% |
| Education | $6.80 | 1 | 0.2% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | $487.25 | 31 | $0 (2024) |
| Lilly USA, LLC | $359.93 | 22 | $0 (2024) |
| Amgen Inc. | $306.28 | 16 | $0 (2024) |
| Janssen Pharmaceuticals, Inc | $277.93 | 15 | $0 (2023) |
| GlaxoSmithKline, LLC. | $269.03 | 12 | $0 (2024) |
| Novo Nordisk Inc | $258.55 | 14 | $0 (2024) |
| Novartis Pharmaceuticals Corporation | $252.05 | 14 | $0 (2024) |
| ABBVIE INC. | $225.15 | 13 | $0 (2024) |
| Bayer Healthcare Pharmaceuticals Inc. | $185.70 | 11 | $0 (2024) |
| Takeda Pharmaceuticals U.S.A., Inc. | $121.24 | 8 | $0 (2021) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $750.62 | 35 | AstraZeneca Pharmaceuticals LP ($209.37) |
| 2023 | $595.08 | 31 | AstraZeneca Pharmaceuticals LP ($138.78) |
| 2022 | $658.93 | 36 | Bayer HealthCare Pharmaceuticals Inc. ($141.82) |
| 2021 | $849.37 | 53 | AbbVie Inc. ($139.66) |
| 2020 | $381.42 | 27 | Lilly USA, LLC ($114.50) |
| 2019 | $108.58 | 7 | Amgen Inc. ($54.86) |
| 2018 | $190.54 | 14 | Boehringer Ingelheim Pharmaceuticals, Inc. ($58.61) |
| 2017 | $13.39 | 1 | Biogen, Inc. ($13.39) |
All Payment Transactions
204 individual payment records from CMS Open Payments — Page 1 of 9
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/16/2024 | Novartis Pharmaceuticals Corporation | ENTRESTO (Drug), LEQVIO | Food and Beverage | In-kind items and services | $18.54 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 12/05/2024 | Otsuka America Pharmaceutical, Inc. | REXULTI (Drug) | Food and Beverage | In-kind items and services | $27.24 | General |
| Category: PSYCHIATRY | ||||||
| 11/13/2024 | Novo Nordisk Inc | Ozempic (Drug), Rybelsus | Food and Beverage | In-kind items and services | $26.46 | General |
| Category: Diabetes | ||||||
| 11/12/2024 | GlaxoSmithKline, LLC. | AREXVY (Drug), TRELEGY ELLIPTA | Food and Beverage | In-kind items and services | $21.60 | General |
| Category: RESPIRATORY | ||||||
| 10/29/2024 | AstraZeneca Pharmaceuticals LP | FARXIGA (Drug) | Food and Beverage | In-kind items and services | $18.32 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 10/10/2024 | AstraZeneca Pharmaceuticals LP | FARXIGA (Drug) | Food and Beverage | In-kind items and services | $21.19 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 10/02/2024 | Bayer Healthcare Pharmaceuticals Inc. | Kerendia (Drug) | Food and Beverage | In-kind items and services | $21.44 | General |
| Category: Cardio-renal | ||||||
| 09/30/2024 | Novartis Pharmaceuticals Corporation | LEQVIO (Drug), ENTRESTO | Food and Beverage | In-kind items and services | $17.88 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 09/18/2024 | Phathom Pharmaceuticals, Inc. | VOQUEZNA (Drug) | Food and Beverage | In-kind items and services | $21.46 | General |
| Category: GASTROENTEROLOGY | ||||||
| 09/16/2024 | GlaxoSmithKline, LLC. | AREXVY (Drug), TRELEGY ELLIPTA | Food and Beverage | In-kind items and services | $26.31 | General |
| Category: RESPIRATORY | ||||||
| 09/09/2024 | Amgen Inc. | Otezla (Drug), Repatha | Food and Beverage | In-kind items and services | $30.04 | General |
| Category: Inflammation | ||||||
| 09/04/2024 | AstraZeneca Pharmaceuticals LP | FARXIGA (Drug) | Food and Beverage | In-kind items and services | $14.45 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 08/26/2024 | Novartis Pharmaceuticals Corporation | LEQVIO (Drug) | Food and Beverage | In-kind items and services | $25.92 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 08/20/2024 | AstraZeneca Pharmaceuticals LP | FARXIGA (Drug) | Food and Beverage | In-kind items and services | $15.07 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 07/18/2024 | Novo Nordisk Inc | Wegovy (Drug) | Food and Beverage | In-kind items and services | $15.48 | General |
| Category: Obesity | ||||||
| 07/16/2024 | Novo Nordisk Inc | Rybelsus (Drug), Ozempic | Food and Beverage | In-kind items and services | $22.06 | General |
| Category: Diabetes | ||||||
| 07/12/2024 | ABBVIE INC. | QULIPTA (Drug), UBRELVY | Food and Beverage | In-kind items and services | $30.47 | General |
| Category: NEUROSCIENCE | ||||||
| 07/10/2024 | AstraZeneca Pharmaceuticals LP | FARXIGA (Drug) | Food and Beverage | In-kind items and services | $18.49 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 06/27/2024 | Amgen Inc. | Repatha (Biological) | Food and Beverage | In-kind items and services | $22.78 | General |
| Category: Cardiology | ||||||
| 06/25/2024 | Novartis Pharmaceuticals Corporation | ENTRESTO (Drug), LEQVIO | Food and Beverage | In-kind items and services | $21.25 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 05/28/2024 | AstraZeneca Pharmaceuticals LP | FARXIGA (Drug) | Food and Beverage | In-kind items and services | $14.16 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 04/29/2024 | AstraZeneca Pharmaceuticals LP | FARXIGA (Drug) | Food and Beverage | In-kind items and services | $17.55 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 04/10/2024 | Novo Nordisk Inc | Rybelsus (Drug), Ozempic | Food and Beverage | In-kind items and services | $18.93 | General |
| Category: Diabetes | ||||||
| 04/02/2024 | AstraZeneca Pharmaceuticals LP | FARXIGA (Drug) | Food and Beverage | In-kind items and services | $14.82 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 03/19/2024 | GlaxoSmithKline, LLC. | TRELEGY ELLIPTA (Drug) | Food and Beverage | In-kind items and services | $34.91 | General |
| Category: RESPIRATORY | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 7 | 478 | 1,018 | $261,210 | $68,355 |
| 2022 | 6 | 431 | 1,024 | $286,860 | $75,901 |
| 2021 | 6 | 383 | 972 | $278,818 | $81,628 |
| 2020 | 3 | 333 | 949 | $271,537 | $66,398 |
Total Patients
1,625
Total Services
3,963
Medicare Billing
$292,283
Procedure Codes
22
All Medicare Procedures & Services
22 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 190 | 627 | $193,800 | $49,057 | 25.3% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 116 | 215 | $42,934 | $11,696 | 27.2% |
| 99496 | Transitional care management services for problem of high complexity | Office | 2023 | 11 | 14 | $9,206 | $2,698 | 29.3% |
| G0444 | Annual depression screening, 5 to 15 minutes | Office | 2023 | 124 | 124 | $5,580 | $2,197 | 39.4% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 14 | 14 | $5,754 | $1,375 | 23.9% |
| 99497 | Advance care planning, first 30 minutes | Office | 2023 | 12 | 12 | $2,736 | $728.85 | 26.6% |
| 87635 | Amplifed dna or rna probe detection of severe acute respiratory syndrome coronavirus 2 (covid-19) antigen | Office | 2023 | 11 | 12 | $1,200 | $603.36 | 50.3% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 218 | 720 | $216,000 | $57,104 | 26.4% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 127 | 217 | $42,098 | $12,096 | 28.7% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 36 | 36 | $14,685 | $3,109 | 21.2% |
| 99496 | Transitional care management services for problem of high complexity | Office | 2022 | 11 | 11 | $6,864 | $1,960 | 28.6% |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | Office | 2022 | 22 | 23 | $2,300 | $1,165 | 50.6% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2022 | 17 | 17 | $4,913 | $467.26 | 9.5% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 210 | 709 | $212,700 | $61,006 | 28.7% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 84 | 166 | $32,204 | $10,731 | 33.3% |
| 99204 | New patient outpatient visit, total time 45-59 minutes | Office | 2021 | 43 | 43 | $17,673 | $4,412 | 25.0% |
| 99496 | Transitional care management services, highly complexity, requiring face-to-face visits within 7 days of discharge | Office | 2021 | 12 | 16 | $9,984 | $3,461 | 34.7% |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | Office | 2021 | 21 | 25 | $2,500 | $1,283 | 51.3% |
| 99203 | New patient outpatient visit, total time 30-44 minutes | Office | 2021 | 13 | 13 | $3,757 | $735.23 | 19.6% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Office | 2020 | 230 | 807 | $241,044 | $58,891 | 24.4% |
| 99213 | Established patient office or other outpatient visit, typically 15 minutes | Office | 2020 | 72 | 111 | $21,534 | $6,021 | 28.0% |
| 99203 | New patient office or other outpatient visit, typically 30 minutes | Office | 2020 | 31 | 31 | $8,959 | $1,487 | 16.6% |
About Dr. Wendell Heidinger, MD
Dr. Wendell Heidinger, MD is a Family Medicine healthcare provider based in Grants Pass, Oregon. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 01/30/2007. The National Provider Identifier (NPI) number assigned to this provider is 1326184607.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Wendell Heidinger, MD has received a total of $3,548 in payments from pharmaceutical and medical device companies, with $750.62 received in 2024. These payments were reported across 204 transactions from 30 companies. The most common payment nature is "Food and Beverage" ($3,541).
As a Medicare-enrolled provider, Heidinger has provided services to 1,625 Medicare beneficiaries, totaling 3,963 services with total Medicare billing of $292,283. Data is available for 4 years (2020–2023), covering 22 distinct procedure/service records.
Ad
Practice Information
- Specialty Family Medicine
- Location Grants Pass, OR
- Active Since 01/30/2007
- Last Updated 06/02/2022
- Taxonomy Code 207Q00000X
- Entity Type Individual
- Practice Solo Practitioner
- NPI Number 1326184607
Products in Payments
- FARXIGA (Drug) $316.65
- XARELTO (Drug) $277.93
- TRELEGY ELLIPTA (Drug) $221.12
- Kerendia (Drug) $185.70
- EMGALITY (Drug) $179.97
- VRAYLAR (Drug) $169.63
- Ozempic (Drug) $137.17
- ENTRESTO (Drug) $129.33
- Otezla (Drug) $119.44
- Vascepa (Drug) $118.39
- BREZTRI (Drug) $92.35
- TRINTELLIX (Drug) $91.17
- MOUNJARO (Drug) $83.93
- UBRELVY (Drug) $80.85
- Aimovig (Biological) $80.49
- HETLIOZ (Drug) $79.72
- LEQVIO (Drug) $79.53
- Rybelsus (Drug) $70.76
- TRULICITY (Drug) $66.42
- Dayvigo (Drug) $64.13
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Family Medicine Doctors in Grants Pass
Dr. Lucien Megna, Md, MD
Family Medicine — Payments: $17,898
Family Medicine $17,898
Dr. Timothy Roberts, M.d, M.D
Family Medicine — Payments: $5,337
Family Medicine $5,337
Dr. Brian Hancock, Md, MD
Family Medicine — Payments: $1,944
Family Medicine $1,944
Minh Nguyen, Md, MD
Family Medicine — Payments: $859.48
Family Medicine $859.48
Dr. Jon Ermshar, M.d, M.D
Family Medicine — Payments: $427.09
Family Medicine $427.09
Dr. M Hill, M.d, M.D
Family Medicine — Payments: $373.29
Family Medicine $373.29